Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…

David Kupfer Biography and Net Worth

Director of Minerva Neurosciences

Dr. David J. Kupfer M.D. serves as Independent Director of the Company. Dr. Kupfer has served on our Board since he was elected by the Board in November 2015. Dr. Kupfer is Distinguished Professor Emeritus of Psychiatry at the University of Pittsburgh School of Medicine, where he chaired that department for 26 years. He also chaired the American Psychiatric Association Task Force for the development of the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders, or DSM-5, which defines the criteria for the diagnosis and classification of mental disorders. Dr. Kupfer received his M.D. from Yale University in 1965. Our Board believes that Dr. Kupfer’s extensive experience in the field of psychiatry qualifies him to serve on our Board.

What is David J. Kupfer's net worth?: The estimated net worth of David J. Kupfer is at least $484,405.48 as of June 26th, 2019. Dr. Kupfer owns 219,188 shares of Minerva Neurosciences stock worth more than $484,405 as of November 21st. This net worth approximation does not reflect any other investments that Dr. Kupfer may own. Learn More about David J. Kupfer's net worth.
How do I contact David J. Kupfer?: The corporate mailing address for Dr. Kupfer and other Minerva Neurosciences executives is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. Minerva Neurosciences can also be reached via phone at (617) 600-7373 and via email at [email protected]. Learn More on David J. Kupfer's contact information.
Has David J. Kupfer been buying or selling shares of Minerva Neurosciences?: David J. Kupfer has not been actively trading shares of Minerva Neurosciences in the last ninety days. Most recently, David Kupfer sold 55,635 shares of the business's stock in a transaction on Wednesday, December 1st. The shares were sold at an average price of $0.88, for a transaction totalling $48,958.80. Learn More on David J. Kupfer's trading history.

David J. Kupfer Insider Trading History at Minerva Neurosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/1/2021	Sell	55,635	$0.88	$48,958.80
6/26/2019	Buy	10,000	$5.55	$55,500.00	219,188
6/21/2016	Buy	55,635	$10.84	$603,083.40	209,188
3/17/2016	Buy	181,488	$5.51	$999,998.88	181,488

David J. Kupfer Buying and Selling Activity at Minerva Neurosciences

Minerva Neurosciences Company Overview

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Today's Range

Now: $2.21

$2.14

$2.23

50 Day Range

MA: $2.55

$2.10

$2.95

2 Week Range

Now: $2.21

$2.07

$13.49

Volume

17,322 shs

Average Volume

52,308 shs

Market Capitalization

$15.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.18